{"id":"NCT00544869","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)","officialTitle":"Phase 3 Open-label, Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure) - an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2007-10-16","resultsPosted":"2014-01-30","lastUpdate":"2014-01-30"},"enrollment":52,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cardiac Edema"],"interventions":[{"type":"DRUG","name":"OPC-41061 ï¼ˆTolvaptan)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To investigate the plasma drug level, efficacy, and safety of 7-day repeated oral administration of OPC-41061 at 15 mg/day (treatment period 1) and subsequent 7-day repeated administration of OPC-41061 at 15 mg/day or 30 mg/day if diuretic effect is insufficient (treatment period 2) in congestive heart failure (CHF) patients with extracellular volume expansion despite conventional diuretic therapy.","primaryOutcome":{"measure":"Body Weight","timeFrame":"Baseline, Day 14 or at the time of final drug administration","effectByArm":[{"arm":"Stopped at End of Treatment Period 1","deltaMin":-2.05,"sd":1.86},{"arm":"Continued at 15 mg/Day","deltaMin":-1.31,"sd":2.95},{"arm":"Dose Escalated to 30 mg/Day","deltaMin":-2.9,"sd":2.69}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["Thirst","Blood Urea Increased","Blood Uric Acid Increased","Blood Creatinine Increased","Blood Glucose Increased"]}}